The invention relates to influenza virus vaccines, and in particular to an influenza virus which has at least its hemagglutinin gene comprising a D222 mutation, and an oseltamivir resistant neuraminidase gene. In some embodiments the influenza virus vaccine further comprises a matrix protein comprising a mutation that increases specific immune response in humans. The virus is useful for production of vaccines against hypervirulent and oseltamivir-resistant influenza.
